Nomexor Plus Hct (Hydrochlorothiazide, Nebivolol)

Hydrochlorothiazide and Nebivolol, the active ingredients in Nomexor Plus Hct, are a thiazide diuretic and a selective β1‑adrenergic blocker presented as tablets for oral use. They are employed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Nomexor Plus Hct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Nomexor Plus Hct combines a thiazide diuretic and a beta‑blocker to treat hypertension and related blood‑pressure disorders.

Essential hypertension: reduces systolic and diastolic pressure in adults. Stage 1 hypertension: helps achieve target blood‑pressure levels. Stage 2 hypertension: provides additional control when monotherapy is insufficient.

Common adverse reactions are generally mild and related to the pharmacologic actions of the two components.

Common Side Effects: - Dizziness - Headache - Increased urination - Fatigue

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Electrolyte disturbances (e.g., hyponatremia, hypokalemia) - Gout flare or pancreatitis

Before prescribing Nomexor Plus Hct, clinicians should consider several safety measures.

Blood pressure monitoring: ensure adequate control and avoid hypotension. Electrolyte assessment: check sodium and potassium levels regularly. Renal function evaluation: adjust use in patients with impaired kidney function. Diabetes management: monitor blood glucose as thiazides may affect glucose tolerance. Concomitant drug review: avoid use with lithium or other β‑blockers without supervision. Store at room temperature: keep tablets in the original container, protect from moisture and light.

Nomexor Plus Hct may interact with several medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Lithium: risk of lithium toxicity increases. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce diuretic efficacy and impair renal function. - Other β‑blockers: additive bradycardia and hypotension.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance hypotensive effect and potassium changes. - Digoxin: increased serum levels when combined with nebivolol. - Warfarin: possible alteration of anticoagulant effect.